Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by porksnifferon Sep 10, 2021 1:16pm
84 Views
Post# 33840411

RE:Just to be clear Porky ...

RE:Just to be clear Porky ...
MrMugsy wrote: You are upset and want to do a character assasination on me because you don't like GUD's growth thus far ?

Do I have that right ?

You'd like to see more growth - because clearly, GUD isn't growing the company ???

Think abbbbbbbout it !

: )

---

Knight Therapeutics

Year Revenue Net Income
2020 199,519,000 32,085,000
2019 47,461,000 18,033,000
2018 12,500,000 24,079,000
2017 8,634,000 17,244,000
2016 5,940,000 18,560,000
2015 1,037,000 34,167,000
2014 365,000 125,859,000

-----




You are overestimating your importance here. You were pumping these equities on the forum and how you were a 'buyer'; this is a fact. You've been posting the same rubbish for years now under multiple alias'. Nobody cares that Goodman has 99% support. It is absolutely meaningless as he has failed and is now pretty much retired. 

All that revenue growth was purchased and massively overpaid for. The higher the revenue the lower the share price. Why? Market is not stupid and this is why this turd is getting punished and will continue to do so as big holders move on to winners and dump losers like GUD. Meanwhile shareholder money in the tens of millions has been spent (and lost) trying to keep this from falling below $5.00 with purchases as high as the $7's making a JRG privatization much cheaper and a certainty if share price continues as is. 

<< Previous
Bullboard Posts
Next >>